Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Sales | 22,319,500 | 21,493,300 | 19,973,800 | 21,222,100 | 19,958,700 |
| Cost of Goods | 4,721,200 | 4,681,700 | 4,447,700 | 5,710,100 | 5,037,200 |
| Gross Profit | 17,598,300 | 16,811,600 | 15,526,100 | 15,512,000 | 14,921,500 |
| Operating Expenses | 12,624,200 | 13,277,800 | 13,523,500 | 12,250,900 | 12,232,300 |
| Operating Income | 4,974,301 | 3,534,500 | 2,003,301 | 3,261,199 | 2,689,400 |
| Other Income | 291,599 | 145,600 | 301,499 | 112,801 | 100,600 |
| Pre-tax Income | 5,265,900 | 3,680,100 | 2,304,800 | 3,374,000 | 2,790,000 |
| Income Tax | 628,000 | 529,500 | 2,391,200 | 636,400 | 381,600 |
| Net Income Continuous | 4,637,900 | 3,150,600 | -86,400 | 2,737,600 | 2,408,400 |
| Net Income Discontinuous | 3,680,500 | 81,400 | -117,700 | N/A | N/A |
| Net Income | $8,318,400 | $3,232,000 | $-204,100 | $2,737,600 | $2,408,400 |
| EPS Basic Total Ops | 8.93 | 3.14 | -0.19 | 2.59 | 2.27 |
| EPS Basic Continuous Ops | 4.98 | 3.07 | -0.08 | 2.59 | 2.27 |
| EPS Basic Discontinuous Ops | 3.95 | 0.07 | -0.11 | N/A | N/A |
| EPS Diluted Total Ops | 8.89 | 3.13 | -0.19 | 2.58 | 2.26 |
| EPS Diluted Continuous Ops | 4.96 | 3.05 | -0.08 | 2.58 | 2.26 |
| EPS Diluted Discontinuous Ops | 3.93 | 0.08 | -0.11 | N/A | N/A |
| EPS Diluted Before Non-Recurring Items | 6.04 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $6,206,901 | $5,143,500 | $3,570,601 | $4,757,799 | $4,117,101 |